Professor Cooper has made contributions in medical science that are relevant to many cancer types including human sarcomas, bladder cancer, kidney cancer and testicular cancer. He is now directing his attention to prostate cancer and is leading a National Cancer Research Institute Collaborative on Prostate Cancer that is designed to develop research projects on prostate cancer throughout the UK. His achievements include:- 1. The identification of14 genes that genetically altered in human cancers (MET, TPR, SYT, SSX1, SSX2, CHN, PSF, NonO, PRCC, TFE3, FGFR1, RAMP, E2F3, ACSL3). 2. He was responsible for cloning the MET oncogene, proposing its unique alpha-beta subunit structure and establishing the role of alterations of MET in cell transformation. 3. He has developed new methods of diagnosing human sarcomas, particularly synovial sarcomas, rhabdomyosarcomas and chondrosarcomas. For example, detection of fusions between the SYT and SSX genes that were identified in his laboratory now provides the most accurate method of diagnosing synovial sarcomas. He has received an international award, The Oswald Vander Veken Prize for this work. 4. Professor Cooper is currently heading one of two National Cancer Research Institute Collaboratives on Prostate Cancer. The aim of this recent initiative is to set up and develop a UK wide research programme on Prostate Cancer that will identify new markers for clinical management, to improve therapies and to increase our understanding of the mechanism of development of this disease. Sucesses of the Collaborative include; (i) the promotion of Active Surveillance as the preferred treatment for patients with early prostate cancer; (ii) the discovery in genome wide association studies of 7 new loci that predispose to the development of prostate cancer; and (iii) the discovery that the drug abiraterone may be used to treat castration-resistant prostate cancer.
Biography Updated on 4 February 2009